A Phase I Dose Escalation and Expanded Cohort Study of P-MUC1C-ALLO1 in Adult Subjects With Advanced or Metastatic Solid Tumors
Details
A Phase 1, open label, dose escalation and expanded cohort study of P-MUC1C-ALLO1 in adult subjects with advanced or metastatic epithelial derived solid tumors, including but not limited to the tumor types listed below.
Eligibility
You can join if...
Inclusion Criteria
-Subjects at least 18 years old with life expectancy of more than 3 months
Must have a confirmed diagnosis (histological or cytological confirmation) of unresectable, locally advanced or metastatic epithelial-derived cancer (including but not limited to breast, ovarian, non-small cell lung, colorectal, pancreatic, and other cancers), refractory to standard of care therapy or ineligible or refused other existing treatment options.
-Subjects of childbearing potential must have a negative serum pregnancy test at screening and a negative urine test within 3 days prior to initiating the lymphodepletion chemotherapy regimen and prior to study drug product administration on Day 0.
Exclusion Criteria
-Has inadequate venous access to administer the study drug.
-Subject currently pregnant or breastfeeding.
-Had major surgery within 3 weeks prior to lymphodepletion or not recovered from prior surgery.